{"id":4465,"date":"2026-11-18T09:00:00","date_gmt":"2026-11-18T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4465"},"modified":"2026-11-21T09:11:54","modified_gmt":"2026-11-21T13:11:54","slug":"nchroma-stops-first-hbv-epigenetic-editing-study","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4465","title":{"rendered":"nChroma Stops First HBV Epigenetic Editing Study"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"512\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_nChroma_Technology_and_Modalities-768x512.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4470\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_nChroma_Technology_and_Modalities-768x512.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_nChroma_Technology_and_Modalities-300x200.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_nChroma_Technology_and_Modalities-1024x683.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261120_nChroma_Technology_and_Modalities.png 1536w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>nChroma Bio<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Clinical study halt and strategic review (previously missed 18 Nov event)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Programmable epigenetic silencing<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>CRMA-1001<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Hepatitis B viral transcription<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Chronic hepatitis B<\/p>\n<h4>Summary<\/h4>\n<p>nChroma disclosed November 18 that it stopped enrollment and dosing in its first CRMA-1001 hepatitis B study and is evaluating strategic alternatives. No efficacy, safety or CMC cause was disclosed, so the setback cannot be assigned to a specific mechanism failure.<\/p>\n<p>The company statement appeared through its corporate social account rather than a dated newsroom release; the CEO separately described continued interest in a next-generation CHARM program. The ClinicalTrials.gov record NCT07200193 had not been reconciled to the company action at discovery. A company restructuring was announced, but a precise workforce reduction was not verified from a primary disclosure. This older item was absent from the prior archive and is explicitly a source-gap recovery.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> halting a first-in-human program may reflect a problem in delivery, target engagement, safety or resource allocation. Counterpoint: none of these causes is stated, and there are no patient-level results.<\/p>\n<p><strong>Interpretation B:<\/strong> portfolio triage could preserve a next-generation epigenetic-silencing design while withdrawing an inferior lead construct. Counterpoint: no comparative data or development timetable are public. HBV requires effective hepatocyte delivery, suppression of both cccDNA and integrated viral transcription, durable silencing without harmful off-target chromatin effects and practical redosing. A stalled registry record should not override the more current company disclosure.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>nChroma develops programmable epigenetic medicines. CRMA-1001 was intended to silence hepatitis B viral transcription through targeted chromatin modification without DNA-sequence editing. Chronic HBV persists through nuclear cccDNA and, for some antigens, integrated viral DNA.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified facts: company and CEO statements.<\/li>\n<li>Missing: reason for stop, number dosed, adverse events, pharmacodynamic HBV markers, cash runway and registry update.<\/li>\n<li>Upgrade: complete trial closeout and next-generation human study with molecular PD.<\/li>\n<li>Downgrade: safety finding or platform abandonment.<\/li>\n<li>Falsifier for a program-specific rather than platform-wide issue: a successor construct reproduces durable suppression at tolerated exposure.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>This is a material negative execution signal for CRMA-1001, with low confidence about why it occurred or what it implies for epigenetic editing more broadly.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: negative for lead program; uncertain for platform. Confidence in Facts: Moderate. Confidence in Interpretation: Low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>nChroma disclosed November 18 that it stopped enrollment and dosing in its first CRMA-1001 hepatitis B study and is evaluating strategic alternatives. No efficacy, safety or CMC cause was disclosed, so the setback cannot&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4470,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1582,97,834],"class_list":["post-4465","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-crma-1001","tag-hepatitis-b","tag-nchroma-bio"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4465","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4465"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4465\/revisions"}],"predecessor-version":[{"id":4489,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4465\/revisions\/4489"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4470"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4465"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4465"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4465"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}